263050.Kq
The company operates in the pharmaceuticals industry, focusing on drug development and medical research, and generates revenue primarily through the sale of pharmaceutical products and related services.
Business. The company operates in the pharmaceuticals industry, focusing on drug development and medical research, and generates revenue primarily through the sale of pharmaceutical products and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on drug development and medical research, and generates revenue primarily through the sale of pharmaceutical products and related services.
The company's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is weak, with a current ratio of 0.44, suggesting that it may struggle to meet short-term obligations. The company's price-to-book ratio is 2.31, and its price-to-tangible-book ratio is also 2.31, indicating that the market is valuing the company's intangible assets at a premium. The company's enterprise value to revenue ratio is 4.51, which is relatively high, suggesting that the market is paying a premium for each dollar of revenue.
The company's profitability is negative, with a return on equity of -1.566 and a return on assets of -0.5807, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income is negative at -25,630,896,360, and its net income is also negative at -23,923,569,790, reflecting significant financial distress. These metrics are far below the industry median for profitability, indicating that the company is underperforming relative to its peers.
The company's revenue is concentrated in a single geographic region, as disclosed in its financial statements, with no specific breakdown provided. The company does not disclose segment-level revenue, making it difficult to assess the contribution of different business lines to overall performance. The lack of segment data limits the ability to evaluate the company's diversification and exposure to different markets.
The company's growth trajectory is negative, with a significant decline in revenue and profitability. The company's operating cash flow is negative at -14,059,760,650, and its free cash flow is also negative at -23,078,155,140, indicating that it is not generating sufficient cash to fund operations or invest in growth. The company's capital expenditure is negative at -647,966,520, suggesting that it is not investing in new projects or expanding its operations. The company's outlook for the current fiscal year is negative, with no indication of improvement in the near term.
The company faces significant financial risks, including a high debt-to-equity ratio and a weak liquidity position. The company's net cash is negative after subtracting total debt, indicating that it may need to raise additional capital or refinance its debt to remain solvent. The company's dilution potential is low, as there is no indication of share issuance or other dilutive events. However, the company's financial distress may lead to the need for equity financing in the future, which could result in dilution for existing shareholders.
The company has not disclosed any recent events, such as filings or transcripts, that would provide insight into its current financial condition or strategic direction. The lack of recent disclosures limits the ability to assess the company's response to market conditions and its plans for addressing its financial challenges. The company's financial statements do not provide detailed information on recent developments, making it difficult to evaluate its prospects for recovery.
- The company is experiencing significant financial distress, with negative operating and net income.
- The company's liquidity position is weak, with a current ratio of 0.44.
- The company's profitability is far below industry medians, indicating underperformance.
- The company is not generating positive cash flows, with both operating and free cash flows being negative.
- The company's capital structure is balanced, but its financial distress may require additional financing.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 263050.KQ Market data — financials · 2026-05-26